Corixa Names Wayne Gombotz Vice President, Process Sciences and Pharmaceutical Development.Business Editors, Health/Medical Writers BIOWIRE2K SEATTLE--(BUSINESS WIRE)--Oct. 28, 2002 Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, announced today the appointment of Wayne R. Gombotz, Ph.D., as vice president, Process Sciences and Pharmaceutical Development. In this post, he will oversee the design and development of all processes Corixa uses to develop products for commercialization. Dr. Gombotz most recently served as senior director, Analytical Chemistry analytical chemistry: see under chemistry. and Formulation at Amgen (formerly Immunex) where he was responsible for analytical characterization, method development, formulation, drug delivery and in-process testing. While at Immunex, he played a major role in the development and launch of ENBREL(R), a drug used to treat rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. . He has 20 years of experience providing technical and administrative direction of clinical and commercial manufacturing operations Manufacturing operations concern the operation of a facility, as opposed to maintenance, supply and distribution, health, and safety, emergency response, human resources, security, information technology and other infrastructural support organizations. , process development, and process validation functions. Prior to working at Amgen, Dr. Gombotz held positions at Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were and Enzytech, Inc. Dr. Gombotz received his Ph.D. in Bioengineering bioengineering Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (see from the University of Washington where he is an affiliate faculty member. He serves as an advisory board member for the University of Washington's Microscale Life Science Center and the Washington Center for Advanced Materials Technology, and serves as an editorial advisory board member of the publication Pharmaceutical Technology. "We are very excited to have someone of Wayne's caliber contribute to our product development function," said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. "His extensive experience in process sciences and pharmaceutical development should benefit the development of our technologies as we place increased emphasis on product commercialization." About Corixa Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , cancer and infectious diseases by understanding and directing the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa currently has 18 programs in clinical development. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, with additional operations in Hamilton, Mont., and South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. . For more information, please visit Corixa's Web site at http://www.corixa.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion